Subject(s)
Delusional Parasitosis/psychology , Dermoscopy/methods , Schizophrenia, Paranoid/psychology , Skin/pathology , Acanthamoeba/parasitology , Antipsychotic Agents/therapeutic use , Benzodiazepines/administration & dosage , Benzodiazepines/therapeutic use , Delusional Parasitosis/drug therapy , Delusional Parasitosis/parasitology , Humans , Male , Middle Aged , Olanzapine , Physician-Patient Relations , Prurigo/pathology , Schizophrenia, Paranoid/complications , Treatment OutcomeSubject(s)
Intellectual Disability/psychology , Memory , Adult , Humans , Male , Psychological TestsSubject(s)
Depression/psychology , Sleep Deprivation , Adult , Aged , Female , Humans , Male , Middle AgedSubject(s)
Transsexualism/surgery , Adolescent , Adult , Child , Female , Humans , Male , Paraphilic Disorders/complications , Psychology , Schizophrenia/complications , Transsexualism/psychologyABSTRACT
Clobazam, a new antianxiety compound, was compared in a double-blind study with diazepam in 40 neurotic outpatients. Twenty-three patients completed the trial under clobazam conditions while 17 patients completed the trial under diazepam conditions. The trial was conducted for a period of four weeks of active drug administration followed by a one-week period of placebo administration. Clobazam was administered in three divided doses of 30 to 40 mg/day, while diazepam was administered in three divided doses of 15 to 20 mg/day, following a fixed dosage schedule. No significant differences were noted between the two treatment conditions during the drug trial period. The patients on clobazam maintained greater improvement during the placebo trial period for the variables "somatic anxiety" and "nights of sleep disturbance." Simultaneous motor coordination tests (hand steadiness test) showed greater improvement on clobazam throughout the trial period in patients with an initial error score greater than 50 points. This difference was significant during the second week of the trial.
